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Summary.-The procoagulant activity of cells from some experimental tumours
isolated in culture or in single-cell suspensions from ascitic fluid was investigated.
Cells from Lewis lungcarcinoma (primaryand metastasis), Ehrlich carcinoma ascites
and JW sarcoma ascites were able to shorten markedly the recalcification time of
normal, Factor VIII- and Factor VII-deficient but not of Factor X-deficient human
plasma. The same cells generated thrombin when mixed with a source of pro-
thrombin and Factor X, absorbed bovine serum (as a source of Factor V), phospho-
lipid and calcium chloride. Thrombin formation was not influenced by the presence
of Factor VII. Cells from Sarcoma 180 ascites were completely inactive in both test
systems. It is concluded that cells from some experimental tumours have the capacity
to activate Coagulation Factor X directly. These findings suggest the existence of an
alternative "cellular" pathway in the initiation ofblood clotting distinct from both the
intrinsic and extrinsic mechanisms.
DEPOSITION of fibrin within and around
tumours has been observed by several
authors, although its precise role in tumour
growth and metastasis formation has not
yet been completely clarified (Hiramoto
et al., 1960; Ogura et al., 1970; Donati et
al., 1977; Peterson, 1977). On the other
hand, it has been known for several years
that malignant disease is associated with
a high incidence of vascular thrombosis or
disseminated intravascular coagulation
(Slichter & Harker, 1974; Pineo et al.,
1974; Goodnight, 1974).
The mechanism of activation of coagu-
lation by cancer cells still remains un-
certain. This has led several investigators
to look for procoagulant activities in
malignant tissues. Procoagulant activity
with characteristics of tissue thrombo-
plastin has been found in human benign
and malignant tumours (O'Meara, 1958;
Boggust et al., 1968; Svanberg, 1975;
Sakuragawa et al., 1977) and in some
experimental tumours (Frank & Hlolvoke,
1968; Holyoke et al., 1972). Pineo et al.
(1973, 1974) reported that partially puri-
fied mucin from secretions ofnon-purulent
chronic bronchitis, ovarian cyst fluid and
saliva, as well as extracts of mucin-
producing adenocarcinomas directly acti-
vated Coagulation Factor X, and sug-
gested that this procoagulant might play
a role in the coagulation disorders of
patients with mucus-secreting adeno-
carcinomas. A similar activity was subse-
quently described by Gordon et al. (1975)
in extracts from human malignant tissues
and from an experimental tumour (rabbit
Xr2 carcinoma) but not in extracts from
normal tissues. This activity appeared to
be related to the presence in the extracts
of a serum protease called Cancer Pro-
coagulant A (CPA; Gordon et al., 1975).
However, it was never established whether
such procoagulant activity was actually
derived from malignant cells.
We therefore studied the procoagulant
activity of cancer cells isolated in cultureACTIVATION OF FACTOR X BY TUMOUR CELLS
or in single-cell suspension from ascitic
fluid, thus avoiding any interference from
connective tissue, muscle, vascular cells or
other common contaminants of tumoral
masses. This paper reports in vitro evi-
dence that cells from some experimental
tumours contribute to fibrin formation by
directly activating Coagulation Factor X.
MATERIALS AND METHODS
Cells and culture techniques
Lewis luing carci.noma (3LL) is transplant-
able i.m. or s.c. in the inbred C57BL/6 mouse,
where it grows locally and produces lung
metastases (McCredie et al., 1965: Frindel
et al., 1967; Simpson-Herren et al.. 1974:
Poggi et al., 1977).
As the tumour has very poor cohesion, it
can normally be disaggregated mechanically.
In these experiments, either the primary
tumour or the lung metastases were ex-
planted in small fragments in primary culture.
Minimum essential medium (MEM) was used
with an extra 3 x MEM vitamins. 3 x MEM
non-essential aininoacids, 15% foetal calf
serum, and 50 ,ug/ml gentamicin. Cells were
washed from outgrowth areas after 3-5 days
by pipetting phosphate-buffered saline (PBS)
solution on to the surface.
Ehrlich carcinoma (Eh.ca) and Sarcoma 180
(8180).-Ascites samples obtained from CD1-
COBS mice with these tumours were directly
suspended in PBS and washed several times
to free them from contaminating erythro-
cytes. These 2 well known tumours are
unable to metastatize unless they are
inoculated into the tibial marrow, from which
they produce lymphnode metastases (Tan-
nock, 1969: Bekesi et al., 1969).
JW sarcoma (JWS) cells.-JWS cells growzn
in ascitic form in BALB/cStCrl mice wAere
prepared as Eh.ca and S180 cells. This trans-
plantable tumour growts intramuscularly and
produces lung metastases (Janik, 1976).
As control cells w%e used the NCTC-1-L929
(L929) cell line derived from C3H mice and
primary cultures of mouse embryonic fibro-
blasts (FET) established in our laboratory
from the osteomuscular structures of mature
litters of C3H mice. Cells from these 2 popu-
lations were grown in MEM on Hanks' base
plus 200% foetal calf serum, 2 x L-glutamine
and 50 ,ug/ml gentamicin. For each sub-
culture, andl for preparation of thie cell sus;-
pensions to be tested, cells wvere detached
from the container by exposure to 0-25%o
trypsin for 5 min.
All types of cultured cells wvere wuashed x 4
in PBS. Cell viability was assessed before the
experiments by trypan-blue exclusion and
wvas more than 85% in all populations except
for 3LL cells, which gave scores of only 70%o.
Cell suspensions Aere adjusted with PBS to
the concentration necessary in our system.
Experiments wvith disrupted cells Awere
made after freezing and thawing ofthe cells or
after sonication.
Cell procoagulant activity
Cell procoagulant activity was evaluated in
2 ways:
1. One-stage plasma-recalcification time.
Platelet-poor citrated human plasma (PPP)
obtained from healthy donors and from
human plasma specimens deficient in Factors
VrIII, VII or X (Dade Division, Pharmaseal,
Trieste, Italy) wvere used as substrates.
Clotting time was determined wsith a mix-
ture of0-1 ml plasma, 0-1 ml cell suspension or
PBS and 041 ml 0-02M CaC12-
2. Assay for Factor-X-activating activity.
This was also a one-stage coagulation time
imeasured on the following mixture: 0-1 ml
cell suspension or PBS, 0-05 ml phospholipid,
0-05 ml absorbed bovine serum (as a source of
Factor V). 0-05 ml partial prothrombin-
complex concentrate (PCC), 0-1 inl purified
human fibrinogen (2 mg/ml) and 041 ml
0-05M CaC12. This test system, adapted from
the one described for platelet coagulant
activity by Semeraro & Vermylen (1977)
selectively measures direct activation of
Factor X (Fig. 1). It contains all the com-
ponents of the common blood coagulation
pathway (i.e. constant amounts of pro-
thrombin and Factor X provided by PCC,
Factor V provided by absorbed bovine serum
and phosplholipid), trace amounts of Factor
VII (present in PCC) and no Factor VIII. In
this mixture which, upon recalcification, is
virtually unclottable (> 30 min), the cells may
activate Factor X either directly or by pro-
viding tissue-factor activity: the latter path-
way. wAhich requires the presence of Factor
VI1. is grossly impaired in our system, thus
making it selectively sensitive to direct
activation of Factor X. Moreover, by adding
optimal concentrations of Factor VI] to the
system, it was possible to obtain a clearcut
listinction betN een the 2 pathwvays.
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tubes placed in a waterbath at 37°C; results of
duplicate experiments were recorded. The
variability in clotting times never exceeded
10% ofthe means.
RESULTS
Table I shows the effect of cells on
plasma recalcification time. Here the
results of experiments with 2 or more
preparations of the same cell type are
reported.
Cells from 3LL (primary and meta-
stasis) and Eh.ca markedly shortened the
recalcification time of normal plasma and
FiG. 1.-Principle of the assay for Factor X
activation.
Thrombofax-Ortho, used as phospholipid,
was obtained from Cilag-Chemie, Milan,
Italy, and purified human fibrinogen from
Kabi AB, Stockholm, Sweden. Bovine serum,
used as a source ofFactor V, was absorbed by
150 mg/ml barium sulphate (Merck, Darm-
stadt, Germany); after absorption this serum
had about 1 u/ml Factor V activity. Partial
prothrombin-complex concentrate (Prothrom-
plex, kindly supplied by Immuno AG,
Vienna, Austria) was dissolved in isotonic
saline and diluted immediately before use to
obtain a solution containing 1 u/ml of pro-
thrombin and Factor X. This preparation
contained about 0.1 u/ml of Factor VII and
had no thrombin and Factor Xa activity
according to previously defined criteria
(Semeraro & Vermylen, 1977). Factor VII
concentrate (FVIIC; Immuno AG) was also
dissolved in isotonic saline and diluted before
use to obtain a solution containing 1 u/ml of
Factor VII.
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Fia. 2.-Dependence of normal plasma recal-
cification time on number of cells.
ofplasmas deficient in Factors VII orVIII.
JWS cells had similar but less activity,
whereas S180 cells had no such effect.
FET shortened the clotting time ofnormal
and Factor VIII-deficient but not of
Factor VII-deficient plasma. L929 cells
were inactive in all systems tested. None
of the cell types studied markedly in-














Plasma recalcification time (range in s)
o. of
Lrations Normal F VIII-def. F VII-def. F X-def.
3 43-53 52-66 46-54 190-228
2 41-49 48-54 40-49 176-210
4 42-48 40-51 43-52 245-289
2 78-93 240-266 80-93 340-385
3 110-118 400-480 121-133 320-355
2 115-122 345-410 130-141 378-405
4 54-66 52-58 108-114 210-239
122-139 488-605 128-139 315-450
PCC
I
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fluenced the recalcification time of Factor
X-deficient plasma.
The effects observed were dependent
upon cell numbers; a typical experiment
is reported in Fig. 2 for 3LL cells. Dis-
ruption of all the cell types studied by
freezing and thawing (vX 3) or by sonication
did not, modify their coagulant activities.
Table II shows the effect of cells in the
assay for Factor X activation. Cells from
3LL, Eh.ca and JWVS gave similar clotting
times with or without Factor V'lI con-
centrate; FET was clearly more active in
the presence of Factor VII concent,rate.
As in plasma recalcification time, SI 80
cells were completely inactive.
Another series of experiments was de-
vised to establish the dependence on Ca++
of cell procoagulant, activity: active cells
wAere incubated with PCC (as source of
prothrombin and Factor X) for various
inttervals; after 0, 2, 4 or 10 min 0 lml
aliquots ofthese mixtures were transferred
to test tubes containing absorbed bovinie
serum, phospholipids, fibrinogen. and
CaCI2; the clotting time recorded did not
vary for all tested systems, indicating that,
Factor X cannot be activated by cells in
the absence ofCa++.
Cell suspensions from Eh.ca and 3LL at,
the concentration of 8 x I06/ml were
cenitrifuged at 4000 rev/min for 10 min;
when the resulting supernatants were
tested in the assay for Factor X activation,
mean clotting times of 146 s and 151 s for
Eh.ca and 3LL respectively were obtained.
The cell suspensions tested before centri-
fugation gave clotting times of 91 s and
110 s respectively. XVben the clotting times
recorded with various dilutions of super-
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FIG. 3. Correlation between different (ilu-
tions of an Eh.ca cell suspenision (8 x 106/
ml) oIr of the correspondting suipernatant,
anid their clotting times in the assay for
Factor X activation.
double-logarithmic paper against the cor-
responding dilutions, a straight line re-
sulted which was parallel to the one re-
lating different Eh.ca cell numbers and the
corresponding clotting times (Fig. 3).
DISCIJSSION
Cell suspensionsfrom some experimental
tumours have procoagulant activity, as
demonstrated by the marked shortening
ofthe clotting time ofnormal plasma after
recalcification. Experiments were there-
fore made to elucidate the mechanism by
which cancer cells accelerated blood clot-
ting in our experimental conditions. Ex-
cept S180, all the cancer cells studied
shortened the one-stage recalcification
time of Factor V1III- and of Factor VII-
deficient, plasmas to a similar extent. The
possibility that coagulation factors ad-
sorbed to cells might be responsible for
these effects is unlikely. Cell activity was
clearly seen in normal plasma, i.e. in the
presence of large amounts of all the clot-
ting factors. In addition, it, remained with
the cells after multiple washings. Since
cancer cells did not require either Factor
V'III or VII, which are key proteins in
intrinsic and extrinsic clotting respect-
ively, most probably they did not act by
either of these pathways. Factor Xa may
have been formed in vivo in the case of
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Eh.ca and JWS ascites and then adsorbed
on to the cells; alternatively, the foetal
calf serum added to the culture medium
might contain trace amounts of Factor
Xa, possibly adsorbed on 3LL cells. Ifthis
were the case, using Factor-X-deficient
plasma instead of normal, Factor VIII- or
VII-deficient plasma, would make no
difference in the recalcification time.
In fact the cancer cells failed to shorten
markedly the clotting time of Factor-X-
deficient plasma. This observation also
ruled out the possibility that cells were
acting on prothrombin or fibrinogen. The
most likely explanation for our results is
that cancer cells themselves possess Fac-
tor-X-activating activity. The slight
shortening in Factor-X-deficient plasma
substrate may be due, at least in part, to
the presence ofsmall amounts ofFactor X
in the substrate. Our contention that the
cancer cells studied have this peculiar pro-
coagulant activity (Factor X activation)
was supported by the results with a rela-
tively purified, sensitive and specific test
system (see Materials and Methods and
Results sections).
In this assay, only the cells which
shortened plasma clotting time were able
to generate thrombin; S180 and the con-
trol cell line L929 were completely in-
effective. Using control cells with throm-
boplastin-like activity (FET) it was clearly
shown that our assay readily discriminates
between direct and Factor ViI1-mediated
activation of Factor X. Taken altogether
our findings suggest the existence of an
alternative "cellular" pathway in blood-
clotting initiation distinct from both
intrinsic and extrinsic mechanisms. A
coagulant activity directly activating
Factor X has recently been described in
human and animal (rabbit, rat, guinea-
pig) platelets (Semeraro & Vermylen,
1977; Semeraro et al., 1979; Tremoli et al.,
1977).
This study confirms and extends the
results obtained by Gordon et al. (1975) on
extracts from human tumours and rabbit
V2 carcinoma; indeed, evidence has been
offered here on pure cell populations that
Factor X activation may be an intrinsic
property of cancer cells. At the moment it
is difficult to propose biological con-
siderations concerning this peculiarity of
tumour cells. The fact that, such an
activity was present also in the super-
natant ofactive cells could have important
physio-pathological implications. The
same type of procoagulant activity was
found both in the 2 metastasizing tumours
(3LL and JWNIS) and Eh.ca, whereas no
procoagulant activity was found in SI80
cells. These data therefore do not suggest
a clear correlation of this activity with
invasiveness; Factor X. activation, how-
ever, could possibly represent a new
parameter for the characterization of
malignant, cells. Whether such an activity
would be relevant to intravascular co-
agulation in tumour-bearing animals or
even in cancer patients remaitns to be
established.
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